RE:The “new strategy” My guess is that since the only 3 analysts that cover it do not focus on the pipeline as the huge value creator and instead still fret over quarterly revenues and EBITDA, they expect higher costs no an earnings miss off their ridiculously high expectations. Since there's no valuation anchoring to the pipeline at this point (or a mild one if you assume the $1+ in option value for SORT1), the brokers are telling clients to expect dull quarter and they sell.
If the analysts don't spend the time to understand what they could have in either oncology or NASH, their clients will be bailing a mere months before potential catalysts that will solidify a completely different picture than what they describe to their clients. It's a shame they aren't actual biotech analysts that factor in the totality of evidence and potential. Oh well, their loss, one hopes.
Another reason they desperately need someone to put the whole picture together, someone that has the background to put all the pieces together and value the possibilities even with high discount rates for the risk,
Bucknelly21 wrote: I think the new strategy is to engage the market less, in that case they are on fire...